COL6A2 and glioma: After 3 weeks of cell inoculation, we performed mouse fluorescence imaging assays on both groups and found that interference with COL6A2 expression significantly inhibited tumor growth in mice compared with the control group, indicating that COL6A2 is a pro-oncogene in gliomas and high expression is detrimental to patient survival (Figure S3A).